XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.25.3

Interests in subsidiaries | 12 Months Ended
--- | ---
Jun. 30, 2025
Investments accounted for using equity method [abstract] |
Interests in subsidiaries | Note 27. Interests in subsidiaries The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:
|  |  |  | Ownership interest |
Name |  | Principal place of business / Country of incorporation |  | 2025 % |  |  | 2024 % |
Kazia Laboratories Pty Ltd |  | Australia |  |  | 100 | % |  |  | 100 | %
Kazia Research Pty Ltd |  | Australia |  |  | 100 | % |  |  | 100 | %
Kazia Therapeutics Inc. |  | United States of America |  |  | 100 | % |  |  | 100 | %
Glioblast Pty Ltd |  | Australia |  |  | 100 | % |  |  | 100 | %

X
- Definition The disclosure of interests in subsidiaries. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 2 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_2_b_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration